Liposomal M-V-05: Formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy

  • Authors:
    • Bee Jen Tan
    • Kiah Shen Quek
    • Man-Yi Wong
    • Wai Keung Chui
    • Gigi N.C. Chiu
  • View Affiliations

  • Published online on: July 1, 2010     https://doi.org/10.3892/ijo_00000669
  • Pages: 211-218
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the management of metastatic breast cancer, fewer recognized therapeutic standards are available as compared to the early stages of the disease. Thus, it is pertinent to search for new, effective therapy to improve survival, tolerability and quality of life of patients. In this study, a liposomal formulation was developed for a novel dihydrofolate reductase (DHFR) inhibitor, M-V-05. Drug encapsulation into liposomes was achieved by the citrate-based, pH gradient loading technique, with a final drug-to-lipid weight ratio of 0.1:1. The liposome formulation exhibited a sustained release profile of the encapsulated drug that followed first order release kinetics. Liposomal M-V-05 was found to be more effective than the standard DHFR inhibitor, methotrexate, and its activity was comparable to liposomal doxorubicin, with IC50 values of 37 and 59 µM achieved in MDA-MB-231 and JIMT-1 cells, respectively. Similar cytotoxicity was observed in primary patient samples of invasive ductal carcinoma of the breast. The combination of liposomal M-V-05 and liposomal doxorubicin in fixed molar ratio of 3:1 was additive in cytotoxicity, allowing the concentrations of liposomal doxorubicin and liposomal M-V-05 to be reduced by 62 and 46%, respectively. Taken together, liposomal M-V-05 represents a promising agent and offers a potential new adjuvant therapy for breast cancer treatment.

Related Articles

Journal Cover

July 2010
Volume 37 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tan BJ, Quek KS, Wong M, Chui WK and Chiu GN: Liposomal M-V-05: Formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy. Int J Oncol 37: 211-218, 2010.
APA
Tan, B.J., Quek, K.S., Wong, M., Chui, W.K., & Chiu, G.N. (2010). Liposomal M-V-05: Formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy. International Journal of Oncology, 37, 211-218. https://doi.org/10.3892/ijo_00000669
MLA
Tan, B. J., Quek, K. S., Wong, M., Chui, W. K., Chiu, G. N."Liposomal M-V-05: Formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy". International Journal of Oncology 37.1 (2010): 211-218.
Chicago
Tan, B. J., Quek, K. S., Wong, M., Chui, W. K., Chiu, G. N."Liposomal M-V-05: Formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy". International Journal of Oncology 37, no. 1 (2010): 211-218. https://doi.org/10.3892/ijo_00000669